Associate
Jamie Barcombe is a European and Chartered (UK) Patent Attorney with a background in biotechnology. His experience extends to drafting, prosecuting and opposing European patent applications directed to a wide array of technologies, including nucleotide therapies, stem cells and biomarkers.
Prior to joining Finnegan, Jamie worked for another large patent law firm in the U.K. He is adept in patent drafting, prosecution, and opposition, and providing strategic advice to clients ranging from global pharmaceutical companies to startups. Jamie has experience managing international portfolios for clinical and pre-clinical candidates and pursuing protection for the candidates themselves in addition to their medical uses, manufacturing methods, and patient subgroups.
Jamie's technical expertise spans the life sciences, covering biologics, biotechnology, clean energy, food and beverage, textiles and pharmaceuticals. He previously worked in research and development (R&D) for a multinational pharmaceutical company and practiced intellectual property management for a world-leading animal health institute, as well as conducted academic research investigating the delivery of therapeutic nucleotides.
European IP Blog
EPO Practice Updated to Enable Electronic Signatures EPO Practice Updated to Enable Electronic Signatures
22 March 2024
Articles
Patent Plausibility Uncertainty Persists, EPO Petition Shows Patent Plausibility Uncertainty Persists, EPO Petition Shows
March 18, 2024
Law360European IP Blog
What Constitutes “Exceptional Circumstances” at the EPO What Constitutes “Exceptional Circumstances” at the EPO
5 January 2024
Event
Secondary Patents on Both Sides of the Pond: Impact of Clinical Trials on Patentability Secondary Patents on Both Sides of the Pond: Impact of Clinical Trials on Patentability
November 2, 2023
Webinar
Event
Patent Drafting for Multiple Jurisdictions Patent Drafting for Multiple Jurisdictions
October 11, 2023
Webinar
European IP Blog
The EPO’s “10 Day Notification Period” Comes to an End The EPO’s “10 Day Notification Period” Comes to an End
11 October 2023
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.